GlobeStar Therapeutics Corporation
GSTC
$0.00
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -57.11% | 157.68% | 48.74% | 47.38% | -62.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.11% | 157.68% | 48.74% | 47.38% | -62.85% |
| Operating Income | 57.11% | -157.68% | -48.74% | -47.38% | 62.85% |
| Income Before Tax | 53.48% | -152.00% | -47.41% | -31.01% | 64.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.48% | -152.00% | -47.41% | -31.01% | 64.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.48% | -152.00% | -47.41% | -31.01% | 64.96% |
| EBIT | 57.11% | -157.68% | -48.74% | -47.38% | 62.85% |
| EBITDA | -- | -- | -- | -- | 94.07% |
| EPS Basic | 56.52% | -130.00% | -21.05% | 0.00% | 76.77% |
| Normalized Basic EPS | 66.67% | -133.33% | -16.67% | -7.69% | 74.58% |
| EPS Diluted | 56.52% | -130.00% | -21.05% | 0.00% | 76.77% |
| Normalized Diluted EPS | 66.67% | -133.33% | -16.67% | -7.69% | 74.58% |
| Average Basic Shares Outstanding | 39.10% | 36.35% | 31.97% | 31.65% | 30.99% |
| Average Diluted Shares Outstanding | 39.10% | 36.35% | 31.97% | 31.65% | 30.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |